| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy |
|
Medicine details |
|
| Medicine name | mavacamten (Camzyos®) |
| Formulation | 2.5 mg, 5 mg, 10 mg and 15 mg hard capsules |
| Reference number | 4028 |
| Indication | Treatment of symptomatic obstructive hyptertrophic cardiomyopathy (oHCM) in adults |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/06/2023 |
| NICE guidance | TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy |